Biosimilar Companies and Market Development Worldwide

4^th International Conference and Exhibition on Biologics & Biosimilars

October 26-28, 2015 Baltimore, USA

Lisa Mueller

Michael, Best & Friedrich

Scientific Tracks Abstracts: J Bioanal Biomed

Abstract :

Biosimilars are highly-similar versions of biological drugs (biologics) approved for the treatment of a variety of disorders and diseases. Originator biologics are the most expensive drugs in the pharmaceutical industry and many cost nearly $100,000 per patient per year. As a result, biologics impose a heavy financial burden on patients and healthcare systems. While patent protection for several biologics has already expired, several other biologics are expected to lose patent protection between now and 2020. This impending patent cliff has given many biotechnology companies the opportunity to develop and market biosimilars with a cost benefit of about 20% to 30%. In order to gain a slice of the $190 billion worth of biologic�s market, many biotechnology companies have ventured into the biosimilar sector. This session will examine the key players that have ventured into this sector as well as the size and development of the market worldwide.

Biography :

Lisa Mueller is a partner in Michael Best’s Intellectual Property Practice Group and the Chair of the Life Sciences and Chemical Industry Group. Ms. Mueller has extensive experience in biotechnology and pharmaceutical sciences. She also has experience in evaluating, filing and securing trademarks, particularly in the pharmaceutical and life sciences area. Ms. Mueller has spoken at Informa’s Conference on Biosimilars and Biotech in Turkey and MENA in November 2014, as well as the ACI’s Biosimilar Conference in June 2014. Ms. Mueller has written extensively about life science issues, including biosimilars, in BRIC and other emerging countries. Samples can be found here: https://bricwallblog.wordpress.com

Email: llmueller@michaelbest.com